Today: 27 April 2026
Browse Category

NASDAQ:META.O 6 January 2026

Meta stock ticks up after-hours as Ray-Ban Display rollout is paused on U.S. demand

Meta stock ticks up after-hours as Ray-Ban Display rollout is paused on U.S. demand

Meta Platforms shares rose 0.3% to $660.62 in after-hours trading after the company paused international expansion of its Ray-Ban Display smart glasses, citing high U.S. demand and limited supply. Waitlists now extend into 2026, delaying launches in the UK, France, Italy, and Canada. Meta named C.J. Mahoney as chief legal officer, replacing Jennifer Newstead. First-quarter unit sales for the glasses reached about 15,000, or 6% market share.
6 January 2026
··

Stock Market Today

  • S&P 500 and Nasdaq Set for Intraday Records Amid Sector Strength and Earnings Focus
    April 27, 2026, 5:02 PM EDT. The S&P 500 and Nasdaq Composite are poised for their 12th and eighth intraday record highs of the year, respectively, driven by strong performances in semiconductors, mega-cap tech, and industrial sectors. Fresh highs emerged in multiple exchange-traded funds (ETFs) including small-cap tech, materials, and sectors like technology and semiconductors. Notable stocks hitting highs span various industries: Casey's in consumer staples; Kirby and Cummins in industrials; Nucor and Linde in materials; and big tech names like Alphabet, Nvidia, Intel, and Taiwan Semiconductor. The momentum continues despite recent concerns over the Strait of Hormuz closure and key May earnings reports. Investors remain focused on the resilience of mega-cap tech and cyclicals, underscoring a broad market advance across sectors and styles.

Latest article

Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push

Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push

27 April 2026
Sagimet Biosciences priced 29.17 million shares at $6 each, seeking to raise $175 million to fund a U.S. Phase 3 acne trial for denifanstat. Shares rose 38% to $8.12 on heavy volume Monday. The company will delay further work on its MASH liver-disease program unless it secures non-dilutive funding. Sagimet reported about $104.5 million in cash and equivalents.
Go toTop